BackgroundCheck.run
Search For

Douglas I Craig, 863040 Edgewood Ave, Schenectady, NY 12306

Known as:
Craig Douglas
Related to:
Anne L Craig

Douglas Craig Phones & Addresses

3040 Edgewood Ave, Schenectady, NY 12306    518-3747044   

Memphis, TN   

Roseland, NJ   

Pomona, CA   

Work

Company: Craig associates Address: 1436 Altamont Ave, Schenectady, NY 12303 Phones: 518-3820739 Position: Chief executive Industries: Elementary and Secondary Schools
Get Report
Control this profile

Mentions for Douglas I Craig

Career records & work history

License Records

Douglas Craig

Licenses:
License #: 56793 - Active
Category: Professional
Issued Date: Dec 17, 2013
Expiration Date: Mar 31, 2020

Douglas Craig resumes & CV records

Resumes

Douglas Craig Photo 50

Mover At Four Hands Moving

Position:
Mover at Four Hands Moving
Location:
Austin, Texas
Industry:
Packaging and Containers
Work:
Four Hands Moving since Oct 2012
Mover Apple through Volt Staffing Jun 2011 - Sep 2011
Application Developer Support Keller Williams Realty Aug 2009 - May 2011
Director of First Impressions Williamson County Association of REALTORS Mar 2008 - Aug 2009
Director of Administration/REALTOR Store Manager Williamson County Assoc. of Realtors Mar 2007 - Aug 2009
Office Administrator Marsh Jan 2007 - Mar 2008
Policy Analyst Marsh USA Jan 2007 - Mar 2008
Policy Analyst Dell Financial Services Apr 2004 - Dec 2006
Operations Coordinator AT&T Wireless Feb 2003 - Mar 2004
Customer Care Representative T Wireless Feb 2003 - Mar 2004
Customer Care Representative Dell Aug 2002 - Feb 2003
Accounts Payable/Receivable Specialist Spherion @ Dell Aug 2002 - Feb 2003
Accounts Payable/Receivable Old Navy Mar 2002 - Aug 2002
Men's and Accessaries Supervisor Department of Public Safety Jan 2001 - Mar 2002
Camera Operator II
Education:
Austin Community College 2001 - 2001
GED
Skills:
Marketing, Management, Customer Service, Negotiation, Project Management, Public Relations, Real Estate, Public Speaking, Investment Properties, Selling, Accounts Payable, Relocation, First Time Home Buyers, Contract Negotiation, Human Resources, Property Management, Real Estate Transactions, Retail, Residential Homes, Sales
Douglas Craig Photo 51

Douglas Craig

Douglas Craig Photo 52

Douglas Craig

Skills:
Design
Douglas Craig Photo 53

Douglas Craig

Douglas Craig Photo 54

Douglas Craig

Douglas Craig Photo 55

Douglas Craig - Putnam Valley, NY

Work:
PrimeGen Media Mar 2012 to 2000
Director Sharp Communications - New York, NY Jun 2006 to Mar 2012
Media Director Envision Marketing - New York, NY Nov 2004 to Jun 2006
Media Director Vector Media - New York, NY Nov 2002 to Oct 2004
New Business Development Manager Primedia Business - New York, NY May 2001 to Nov 2002
Account Executive Miller Freeman, Inc - New York, NY Mar 1998 to May 2001
Account Executive Sader & Associates - New York, NY 1991 to 1998
Media Director Ketchum Advertising - New York, NY 1989 to 1991
Media Planner Grey Advertising - New York, NY 1988 to 1989
Assistant/Media Planner
Education:
SUNY at Oswego - Oswego, NY 1982 to 1987
Bachelor of Arts in Arts/English
Douglas Craig Photo 56

Douglas Craig - Far Rockaway, NY

Work:
Peninsula Hospital - Far Rockaway, NY Nov 1997 to Jan 2012
Perioperative support assoc.
Education:
Manhattan vocational High School - New York, NY 1973 to 1997
Associates @ Boro of manhattan community college N.Y. N.Y. in Liberal Arts

Publications & IP owners

Us Patents

Use Of Agonists Or Antagonists Of The 5-Ht7 Receptor To Treat Disorders Of The Bladder

US Patent:
6440988, Aug 27, 2002
Filed:
Sep 8, 2000
Appl. No.:
09/657665
Inventors:
Douglas A. Craig - Emerson NJ
Assignee:
Synaptic Pharmaceutical Corporation - Paramus NJ
International Classification:
A61K 3144
US Classification:
514285, 514292
Abstract:
The present invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT receptor antagonist or an antagonist that binds to both 5-HT and 5-HT receptors. The invention also provides a method of treating urinary retention in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT receptor agonist or an agonist that activates both 5-HT and 5-HT receptors.

Compounds Specific For The Human 1D Adrenergic Receptor And Uses Thereof

US Patent:
6706716, Mar 16, 2004
Filed:
Jan 17, 2001
Appl. No.:
09/764710
Inventors:
Michael Konkel - Garfield NJ
John M. Wetzel - Fair Lawn NJ
Stewart A. Noble - Wheeling IL
Charles Gluchowski - Danville CA
Douglas A. Craig - Emerson NJ
Assignee:
Synaptic Pharmaceutical Corporation - Paramus NJ
International Classification:
A61P 4300
US Classification:
51425311, 51425312, 544360, 544365
Abstract:
This invention is directed towards a method of inhibiting activation of a human adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human adrenergic receptor. This invention provides for a compound which binds selectively to a human adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.

Dna Encoding Mammalian Neuropeptide Ff (Npff) Receptors And Uses Thereof

US Patent:
6709831, Mar 23, 2004
Filed:
Sep 24, 1999
Appl. No.:
09/405558
Inventors:
Christophe P. G. Gerald - Ridgewood NJ
Kenneth A. Jones - Bergenfield NJ
James A. Bonini - Oakland NJ
Beth E. Borowsky - Montclair NJ
Douglas A. Craig - Emerson NJ
Assignee:
Synaptic Pharmaceutical Corporation - Paramus NJ
International Classification:
G01N 33566
US Classification:
435 72, 435325, 4353201, 435 691, 530350
Abstract:
This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

Dna Encoding Mammalian Neuropeptide Ff (Npff) Receptors And Uses Thereof

US Patent:
6849727, Feb 1, 2005
Filed:
Mar 29, 2000
Appl. No.:
09/538036
Inventors:
Christophe P. G. Gerald - Ridgewood NJ, US
Kenneth A. Jones - Bergenfield NJ, US
James A. Bonini - Oakland NJ, US
Beth E. Borowsky - Montclair NJ, US
Douglas A. Craig - Emerson NJ, US
Assignee:
H.Lundbeck A/S - Copenhagen-Valby
International Classification:
C07H 2104
C12N 1500
C12N 1563
C12N 1512
C07K 1400
US Classification:
536 235, 435 691, 4353201, 435325, 530350
Abstract:
This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

Dna Encoding Mammalian Neuropeptide Ff (Npff) Receptors And Uses Thereof

US Patent:
7252945, Aug 7, 2007
Filed:
Nov 18, 2004
Appl. No.:
10/992407
Inventors:
Christophe P. G. Gerald - Ridgewood NJ, US
Kenneth A. Jones - Bergenfield NJ, US
James A. Bonini - Oakland NJ, US
Beth E. Borowsky - Montclair NJ, US
Douglas A. Craig - Emerson NJ, US
Assignee:
H. Lundbeck A/S - Valby-Copenhagen
International Classification:
C12Q 1/68
G01N 33/53
C12N 15/00
US Classification:
435 6, 435 71, 435455
Abstract:
This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

Dna Encoding Mammalian Neuropeptide Ff (Npff) Receptors And Uses Thereof

US Patent:
7276339, Oct 2, 2007
Filed:
Nov 18, 2004
Appl. No.:
10/992577
Inventors:
Christophe P. G. Gerald - Ridgewood NJ, US
Kenneth A. Jones - Bergenfield NJ, US
James A. Bonini - Oakland NJ, US
Beth E. Borowsky - Montclair NJ, US
Douglas A. Craig - Emerson NJ, US
Assignee:
H. Lundbeck A/S - Valby
International Classification:
C12Q 1/68
G01N 33/53
C12N 15/00
US Classification:
435 6, 435 71, 435455
Abstract:
This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

Use Of Compounds Which Activate A 5-Ht Receptor To Treat Urinary Incontinence

US Patent:
2003000, Jan 2, 2003
Filed:
Nov 29, 1999
Appl. No.:
09/450880
Inventors:
DOUGLAS A. CRAIG - EMERSON NJ, US
International Classification:
A61K031/405
US Classification:
514/415000, 514/019000
Abstract:
The invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT receptor agonist.

Use Of Agonists Or Antagonists Of The 5-Ht7 Receptor To Treat Disorders Of The Bladder

US Patent:
2003003, Feb 13, 2003
Filed:
Aug 26, 2002
Appl. No.:
10/228779
Inventors:
Douglas Craig - Emerson NJ, US
Assignee:
Synaptic Pharmaceutical Corporation
International Classification:
A61K031/00
US Classification:
514/001000
Abstract:
The present invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HTreceptor antagonist or an antagonist that binds to both 5-HTand 5-HTreceptors. The invention also provides a method of treating urinary retention in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HTreceptor agonist or an agonist that activates both 5-HTand 5-HTreceptors.

Isbn (Books And Publications)

Fireside Politics: Radio And Political Culture In The United States, 1920-1940

Author:
Douglas B. Craig
ISBN #:
0801864399

Fireside Politics: Radio And Political Culture In The United States, 1920-1940

Author:
Douglas B. Craig
ISBN #:
0801883121

Possible Relatives

Cynthia T Craig  David W Craig  Dawn D Craig  Dawna Craig  Dax C Craig  Dayle K Craig  Dayna P Craig  Douglas P Johnson  Douglas R Stamps  Douglas J Standish 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.